The Latest

Cutting-edge Modalities Giving Health Professionals an Edge Against Alzheimer’s Disease

John Q Walker, Ph.D., the Co-founder, and Chief Technology Officer of uMethod Health, recently participated in a distinguished panel of experts in the field of disease. The discussion centered around translating technological advancements into actionable strategies at a clinical level. Together, the panel delved into the realm of proactive, precision, and holistic medicine, identifying it as the next frontier in healthcare. Dr. Walker describes how uMethod is at the forefront…READ MORE

Alzheimer’s Disease: Separating Fact from Fiction

Michael K. Racke, MD, medical director of neurology at Quest Diagnostics, delved into some commonly-believed myths about Alzheimer disease and provided his insight on the scientific explanations for these assumptions. Common myths:#1: Only older patients need to worry about AD. #2: AD is primarily an inherited genetic disease. #3: Most patients don’t want to know if they are at risk of developing AD. #4: Only high-powered imaging tests can help evaluate for AD. #5: Only…READ MORE

A PACT to Preserve Veterans’ Health

The US Senate passed the Promise to Address Comprehensive Toxics (PACT) Act on August 2, 2022. The PACT healthcare bill is a positive step toward assisting the 3.5 million veterans affected by exposure to toxins during military service. The debate surrounding the PACT legislation drew attention to a stark fact: too many of America’s veterans live with ill health. In 2020, the Veterans Administration National Center for PTSD conducted a…READ MORE

uMETHOD Health Highlights Factors Contributing to Cognitive Decline for Alzheimer’s Awareness Month

As a part of its efforts during Alzheimer's Awareness Month, uMETHOD is educating the public on the risk factors associated with Alzheimer's and the importance of early intervention. Alzheimer's disease is a progressive brain disorder that affects 5.7 million U.S. adults, with many more in preceding stages of decline. The impacts of the disease are devastating and extend beyond memory loss. Alzheimer's and dementia can bring pain, stress, financial ruin,…READ MORE

Tribal Diagnostics Announces Availability of Personalized Alzheimer’s and Dementia Care Plans Via Partnership with uMETHOD Health

OKLAHOMA CITY, Oct. 17, 2023 -- Tribal Diagnostics, a high-complexity diagnostics laboratory, has announced availability of the RestoreU™ Dementia Panel throughout Texas and Oklahoma. RestoreU is a risk assessment and care plan service created by uMETHOD Health, a health technology company specializing in precision medicine for chronic diseases, to help physicians close care gaps for patients with cognitive decline. RestoreU's Assistive AI improves care for individuals suffering from chronic diseases like Alzheimer's with multiple underlying medical causes. It creates…READ MORE

Embracing Data and Technology to Help Slow Alzheimer’s and Dementia

Alzheimer’s is a disease of data. The disease doesn’t have what we typically react to quickly: There is no pain, no blood, no pus, no rash, no dry mouth, nothing is visibly out of kilter.  Yet, Alzheimer’s disease generally starts its destruction 20 years before symptoms (most notably memory loss) are acknowledged. There can be more than 50 treatable causes to be dealt with simultaneously. More than half of the…READ MORE

Raleigh-based SaaS Platform uMETHOD Health Tackles Alzheimer’s Disease With AI

Raleigh-based uMethod was founded in 2013 to help doctors treat patients suffering from cognitive problems like dementia and Alzheimer’s. The SaaS platform provides a service to doctors, who order blood tests for a patient suffering from cognitive decline in order to create a personalized AI-generated care plan.  AI collects data on patients from blood tests ordered by their doctor and devises a treatment plan by analyzing treatable causes such as infection, inflammation,…READ MORE

Fighting Alzheimer’s with AI: Raleigh company working with global giant to develop treatment plans

RESEARCH TRIANGLE PARK –  Alzheimer’s Disease and dementia have long been feared by many, especially those with first-hand experience. Vik Chandra, CEO and co-founder of uMETHOD is familiar with this disease having seen it in both his grandmother and mother-in-law. According to Chandra, there are 17 and a half million Medicare-aged patients somewhere on a spectrum of cognitive decline, and about 150,000 doctors across the country caring for these patients. He is passionate…READ MORE

Lab Pulse video interview: Detecting potentially treatable causes of cognitive decline

Quest Diagnostics recently announced the nationwide availability of the RestoreU Dementia Panel, an artificial intelligence (AI)-based risk assessment and care service created by uMETHOD Health. In this video interview, Dr. Michael K. Racke, medical director for neurology at Quest Diagnostics, spoke to Stephen Wellman, director of content and strategy at LabPulse and The Science Advisory Board, about the challenges associated with identifying those who do not have Alzheimer's and may…READ MORE

NJ Biz: Quest Diagnostics adds AI-based testing to dementia portfolio

Quest Diagnostics unveiled a new artificial intelligence-based test service in the U.S. that aims to help physicians improve the detection of dementia and create better outcomes for patients. Through a partnership with Raleigh, N.C.-based health technology company uMETHOD Health, the Secaucus-headquartered testing provider added the RestoreU Dementia Panel to its testing portfolio, according to a May 4 announcement. Dr. Michael Racke, Quest’s neurology medical director, said, “With so much attention on emerging therapies for…READ MORE